Perilous Reversal Stock: AcelRx Pharmaceuticals (ACRX)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified AcelRx Pharmaceuticals ( ACRX) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified AcelRx Pharmaceuticals as such a stock due to the following factors:

  • ACRX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $22.1 million.
  • ACRX has traded 558,548 shares today.
  • ACRX is down 3% today.
  • ACRX was up 6.7% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ACRX with the Ticky from Trade-Ideas. See the FREE profile for ACRX NOW at Trade-Ideas

More details on ACRX:

AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain (BTP). Currently there are 4 analysts that rate AcelRx Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for AcelRx Pharmaceuticals has been 1.1 million shares per day over the past 30 days. AcelRx has a market cap of $282.8 million and is part of the health care sector and health services industry. The stock has a beta of 1.84 and a short float of 24.4% with 2.39 days to cover. Shares are down 38.5% year-to-date as of the close of trading on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Here's Why AcelRx Pharmaceuticals (ACRX) Stock Gained Today

AcelRx Pharmaceuticals (ACRX) Highlighted As Weak On High Volume

AcelRx Pharmaceuticals (ACRX) Strong On High Relative Volume Today

Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters

5 Stocks Poised for Breakouts